beta thalassaemia Archives

bluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

https://pharmaphorum.com/news/bluebird-trumpets-long-term-data-from-beta-thalassaemia-gene-therapy/

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta

ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders

https://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/

Bristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

https://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/

Data on the first two patients to be treated with a CRISPR-based drug for the blood disorders beta

CRISPR trials yield encouraging data in blood disorders

https://pharmaphorum.com/news/crispr-trials-yield-encouraging-data-in-blood-disorders/

The FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the

Celgene scores FDA okay for thalassaemia drug Reblozyl

https://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/

bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its

bluebird claims first approval for gene therapy Zynteglo in EU

https://pharmaphorum.com/news/bluebird-claims-first-approval-for-gene-therapy-zynteglo-in-eu/

beta thalassaemia